Samsara BioCapital, a leading biotech investor active across private and public markets, joins global investor syndicate

轮回生物资本（Samsara BioCapital），一家在私募和公开市场均活跃领先的生物技术投资者，加入了全球投资者财团。

Funds will be used to advance AP306, a first-in-class pan phosphate transporter inhibitor in development as a monotherapy for hyperphosphatemia in patients on dialysis

资金将用于推进AP306的研发，这是一种首创的泛磷酸盐转运蛋白抑制剂，正作为单药疗法用于治疗透析患者的高磷血症。

Investment comes ahead of Phase 2b topline data, expected in H1 2027

此次投资先于预计于2027年上半年公布的2b期主要终点数据

REDWOOD CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- R1 Therapeutics, Inc (“R1”), a clinical-stage biopharmaceutical company developing first-in-class therapies for patients with kidney disease, today announced an expansion of its Series A financing to $80.5 million, with new investment from Samsara BioCapital..

加利福尼亚州雷德伍德城，2026年9月30日（环球新闻社）——R1 Therapeutics, Inc.（“R1”），一家致力于开发针对肾病患者首创疗法的临床阶段生物制药公司，今日宣布其A轮融资规模扩大至8,050万美元，并获得Samsara BioCapital的新投资。

Samsara BioCapital joins an investor syndicate that includes Abingworth, DaVita Venture Group, F-Prime, Curie.Bio, SNMA Capital (previously Symbiosis Capital Management) and U.S. Renal Care, following the oversubscribed $77.5 million round announced in March 2026. The proceeds will support the continued development of R1’s lead asset, AP306, a first-in-class pan phosphate transporter inhibitor, which is currently being evaluated as a monotherapy in a global Phase 2b trial for hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.

在2026年3月宣布的超额认购的7,750万美元融资之后，Samsara BioCapital加入了一个由Abingworth、DaVita Venture Group、F-Prime、Curie.Bio、SNMA Capital（前身为Symbiosis Capital Management）和U.S. Renal Care组成的投资者财团。所得资金将用于支持R1公司核心资产AP306的持续开发；AP306是一款首创的泛磷酸盐转运蛋白抑制剂，目前正作为单药疗法在一项针对接受透析的慢性肾脏病（CKD）患者高磷血症的全球IIb期临床试验中进行评估。

Topline data from the trial are expected in the first half of 2027..

预计该试验的顶层数据将于2027年上半年公布。

Krishna Polu, M.D., Co-Founder, President and CEO of R1 Therapeutics, said:

R1 Therapeutics 联合创始人、总裁兼首席执行官 Krishna Polu 医学博士表示：

“Samsara brings a rare combination of scientific depth and a track record of investing in kidney companies across the private and public markets. Their decision to join

“Samsara 带来了罕见的科学深度以及在公私市场投资肾脏病企业的卓越业绩。他们决定加入

ahead of the Phase 2b readout is a strong endorsement of our novel approach to addressing hyperphosphatemia. With our global trial underway, their support, alongside that of our existing syndicate, further strengthens our ability to generate the clinical data needed to bring AP306 to patients.”

在二期b临床试验结果公布之前，这强有力地认可了我们针对高磷血症的创新方法。随着全球临床试验的推进，他们以及我们现有财团的支持，进一步增强了我们生成将AP306带给患者所需的临床数据的能力。”

Abe Bassan, Partner at Samsara BioCapital, added:

Samsara BioCapital 合伙人 Abe Bassan 补充道：

'Managing phosphate levels remains one of the greatest challenges in dialysis care, with limited innovation for patients over the past several decades. With AP306, R1 is pursuing a novel mechanism of action that inhibits active phosphate transport, offering a differentiated alternative to traditional phosphate binders.

控制磷酸盐水平仍然是透析护理中最大的挑战之一，过去几十年来针对患者的创新有限。通过AP306，R1正在探索一种抑制活性磷酸盐转运的新作用机制，为传统磷酸盐结合剂提供一种差异化的替代方案。

We are pleased to join the investor syndicate and look forward to supporting the team as they advance AP306 through Phase 2b and beyond.”.

我们很高兴加入投资者联盟，并期待在团队推进AP306完成IIb期临床试验及后续阶段的过程中提供支持。

Phosphate binders have been the standard of care for 60 years,

磷酸盐结合剂已成为标准治疗方案长达60年，

1

1

yet more than 70% of US dialysis patients fail to achieve normal phosphate levels,

然而，超过70%的美国透析患者未能达到正常的磷酸盐水平，

2

2

and uncontrolled hyperphosphatemia contributes to cardiovascular disease, bone disease and mortality.

且不受控制的高磷血症会导致心血管疾病、骨骼疾病和死亡。

3

3

AP306 is the only agent that blocks the 'active' transport of phosphate, targeting three key transporters in the gut, with the potential for rapid, effective phosphate lowering at a substantially reduced treatment burden.

AP306是唯一一种阻断磷酸盐“主动”转运的药物，靶向肠道中的三种关键转运蛋白，有望在显著降低治疗负担的同时，快速有效地降低磷酸盐水平。

The multi-center, randomized, double-blind, placebo-controlled Phase 2b study (

这项多中心、随机、双盲、安慰剂对照的2b期研究（

NCT06712654

NCT06712654

) is being conducted at clinical sites across the US and in China through R1's global partnership with Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) ('Alebund').

）正在通过 R1 与宜联生物医药（江苏）有限公司（港交所股票代码：09637，简称“宜联生物”）的全球合作伙伴关系，在美国和中国的临床站点开展。

For further information:

如需更多信息：

Optimum Strategic Communications

奥普蒂姆战略传播

Mary Clark, Isabelle Abdou, Eleanor Cooper

玛丽·克拉克，伊莎贝尔·阿布杜，埃莉诺·库珀

Tel: +44 20 3922 0900

电话：+44 20 3922 0900

Email:

电子邮件：

r1therapeutics@optimumcomms.com

r1therapeutics@optimumcomms.com

About R1 Therapeutics

关于R1 Therapeutics

R1 Therapeutics is a clinical-stage biopharmaceutical company focusing on the development of first-in-class therapies for patients with kidney disease. Its lead program, AP306, targets hyperphosphatemia in patients with chronic kidney disease on dialysis, a condition associated with serious bone and cardiovascular complications and poorer outcomes when phosphate remains uncontrolled.

R1 Therapeutics 是一家处于临床阶段的生物制药公司，专注于为肾病患者开发首创疗法。其核心项目 AP306 针对接受透析的慢性肾病患者的低磷血症，这是一种在磷酸盐水平未得到控制时与严重的骨骼和心血管并发症以及更差的预后相关的疾病。

AP306 is a first-in-class pan phosphate active transport inhibitor designed to block three key phosphate transporters in the gut, with the potential to deliver rapid and effective phosphate lowering with a significantly reduced treatment burden. R1 has licensed exclusive global rights outside of Greater China to AP306 from Alebund Pharmaceuticals and is advancing a global Phase 2b development program.

AP306 是一款首创的泛磷酸盐主动转运抑制剂，旨在阻断肠道中的三种关键磷酸盐转运蛋白，有望在显著降低治疗负担的同时，实现快速且有效的降磷效果。R1 已从 Alebund Pharmaceuticals 获得 AP306 在大中华区以外的全球独家权利，并正在推进一项全球 IIb 期开发计划。

AP306 was originally discovered by Chugai Pharmaceutical Co., Ltd. and subsequently licensed to Alebund Pharmaceuticals in 2021. R1 launched in March 2026 with an oversubscribed $77.5 million Series A financing co-led by Abingworth, DaVita Venture Group, and F-Prime, with participation from Curie.Bio, SNMA Capital and U.S.

AP306 最初由中外制药株式会社发现，随后于 2021 年授权给 Alebund Pharmaceuticals。R1 于 2026 年 3 月启动，完成了超额认购的 7,750 万美元 A 轮融资，该轮融资由 Abingworth、DaVita Venture Group 和 F-Prime 联合领投，Curie.Bio、SNMA Capital 和 U.S. 参与投资。

Renal Care. The round was subsequently expanded to $80.5 million with the addition of Samsara BioCapital. For more information, visit .

肾脏护理。随着Samsara BioCapital的加入，该轮融资随后扩大至8,050万美元。欲了解更多信息，请访问。

www.r1therapeutics.com

www.r1therapeutics.com

and follow R1 on

并关注 R1

LinkedIn

领英

.

。

About Samsara BioCapital

关于 Samsara BioCapital

Founded in 2017, Samsara BioCapital is a leading biotech investment firm focused on identifying opportunities across public and private markets. Samsara invests across the full spectrum from early-stage start-up to late-stage clinical assets with a focus on companies that will have a significant impact on patients and address high unmet medical needs.

Samsara BioCapital 成立于2017年，是一家领先的生物技术投资公司，专注于在公开和私募市场中发掘投资机会。Samsara 的投资覆盖从早期初创企业到后期临床资产的全阶段，重点投资于那些将对患者产生重大影响并满足高度未竟医疗需求的公司。

Samsara works with entrepreneurs and top-tier management teams that they believe will have a meaningful impact on innovative therapeutics. The Samsara team has deep expertise in biotech with significant experience working together prior to founding the firm. The team is led by Srinivas Akkaraju, who has over twenty-two years of industry experience and has an MD and a PhD in Immunology from Stanford University..

Samsara 与那些他们认为将在创新疗法领域产生重要影响的创业者及顶级管理团队携手合作。Samsara 团队在生物科技领域拥有深厚的专业知识，并在创立公司之前就已积累了丰富的协作经验。该团队由 Srinivas Akkaraju 领导，他拥有超过二十二年的行业经验，并持有斯坦福大学免疫学博士（PhD）和医学博士（MD）学位。

References

参考文献

Fissel R et al. 2016 Phosphate binder pill burden, patient-reported non-adherence, and mineral bone disorder markers: Findings from the DOPPS.

Fissel R 等，2016 年。磷酸盐结合剂的药片负担、患者报告的非依从性以及矿物质骨紊乱标志物：来自 DOPPS 的研究结果。

Hemodial Int.

血液透析国际

2016 January; 20(1): 38–49. doi:10.1111/hdi.12315

2016年1月；20(1): 38–49。doi:10.1111/hdi.12315

United States Renal Data System. 2024. USRDS 2024 Annual Data Report. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

美国肾脏数据系统。2024年。USRDS 2024年度数据报告。美国国立卫生研究院，美国国家糖尿病、消化和肾脏疾病研究所。

Ketteler M, Block GA, Evenepoel P, et al. 2017 Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters.

Ketteler M, Block GA, Evenepoel P, 等. 《2017年KDIGO慢性肾脏病-矿物质和骨异常（CKD-MBD）指南更新执行摘要》：变化内容及其重要性。

Kidney Int.

《肾脏国际》

2017;92:26–36

2017;92:26–36